A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing dementia. That’s a potential game changer for the more than 6 million Americans diagnosed each year and the 100,000 who die from the memory-robbing disease annually.

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable Semaglutide) - a once-weekly glucagon-like peptide-1 receptor

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from the pharmaceutical giant.